Industry: Pharmaceuticals and Biotech
TIKOMED AB is a privately, owned company based in Viken, Sweden. Tikomed is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program).
TIKOMED’s drug candidate, ILB® is a patented Dextran Sulphate which addresses the underlying causes of neurodegeneration in acute and chronic diseases. ILB® targets multiple cellular pathways responsible for the loss of neuron structure or function seen in the neurodegenerative disease processes, boosting self-repair and protection, enabling neurons to regain lost functions.